<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03505138</url>
  </required_header>
  <id_info>
    <org_study_id>CRONEX3.0</org_study_id>
    <nct_id>NCT03505138</nct_id>
  </id_info>
  <brief_title>Impact of Telemedicine in the Rate of Readmission for COPD. Project CRONEX 3.0</brief_title>
  <official_title>Impact of Telemedicine in the Rate of Readmission for COPD and Cost-effectiveness Analysis (e- Pneumo ) : Project CRONEX 3.0</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sociedad Española de Neumología y Cirugía Torácica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sociedad Española de Neumología y Cirugía Torácica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of COPD is high and suppose one of the first public health problem in the
      world. It has a high morbidity and mortality and healthcare costs. The economic aspect is
      directly related to hospitalization, accounting for 45-50% of total expenditure of COPD.
      Patients with frequent exacerbations generate most of the cost.

      In these patients, there are not standardized treatments or monitoring in a medium or long
      term, but it seems reasonable that the combination of various interventions (programs
      self-care, active role of health professionals in consultations, home programs, group visits,
      establishment action plans for patients, use of communication technologies or social
      networks) may improve many patient outcomes.

      The hypothesis of our work will be to introduce telemedicine platform to establish action
      plans for the patient, recognition of symptoms and exacerbations, treatments for the
      exacerbations, training material on COPD, smoking and inhalation therapy, establishment of a
      fast and fluid communication with pulmonologist, with the purpose of responding to various
      health problems that patients with COPD (exacerbator phenotype or ACO phenotype) may have. We
      will study the impact of this tool to reduce the rate income or readmission for the patients
      with COPD, analyzing it from the perspective of cost-effectiveness.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess whether a telematic program intervention can decrease the rate of readmissions in patients with COPD, comparing with conventional management.</measure>
    <time_frame>one year</time_frame>
    <description>outcome measure: the rate of readmissions during the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Conducting a cost-effectiveness study that allows us to estimate the incremental cost-effectiveness ratio (ICER) of this patient group compared with the control group.</measure>
    <time_frame>one year</time_frame>
    <description>outcome measure: incremental cost-effectiveness ratio (ICER) between these two arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the quality of life of COPD patients by measuring CAT in study groups</measure>
    <time_frame>one year</time_frame>
    <description>outcome measure: quality of life measured by CAT questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To study the evolution of lung function in both groups after 1 year of follow up.</measure>
    <time_frame>one year</time_frame>
    <description>outcome measure: lung function by spirometry (FEV1/FVC, FVC, FEV1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analyze the survival at 12 months follow-up in each group.</measure>
    <time_frame>one year</time_frame>
    <description>outcome measure: number of deaths in each group to see the survival in this study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analyze a biomarker predictor of exacerbation severity.</measure>
    <time_frame>one year</time_frame>
    <description>outcome measure: PCR (mg/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analyze the inhaler compliance and adherence of treatment in both groups.</measure>
    <time_frame>one year</time_frame>
    <description>outcome measure: Morisky-Green´s scoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Make satisfaction survey patients and caregivers, comparing both study groups.</measure>
    <time_frame>one year</time_frame>
    <description>outcome measure: satisfaction (very satisfied, satisfied, unsatisfied, very unsatisfied)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the quality of life of patients by measuring EQ-5D in study groups</measure>
    <time_frame>one year</time_frame>
    <description>outcome measure: EQ-5D questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analyze a biomarker predictor of exacerbation severity.</measure>
    <time_frame>one year</time_frame>
    <description>outcome measure: fibrinogen (g/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analyze a biomarker predictor of exacerbation severity.</measure>
    <time_frame>one year</time_frame>
    <description>outcome measure: leukocytes (mil/mm3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analyze a biomarker predictor of exacerbation severity.</measure>
    <time_frame>one year</time_frame>
    <description>outcome measure: eosinophils (mil/mm3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analyze a biomarker predictor of exacerbation severity.</measure>
    <time_frame>one year</time_frame>
    <description>outcome measure: pro-BNP (pg/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analyze a biomarker predictor of exacerbation severity.</measure>
    <time_frame>one year</time_frame>
    <description>outcome measure: cholesterol (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analyze a biomarker predictor of exacerbation severity.</measure>
    <time_frame>one year</time_frame>
    <description>outcome measure: proteins (mg/dL)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Group intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional management for COPD will take place in our health care system more telematics intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Is performed only conventional management of COPD in our health care system.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Group intervention</intervention_name>
    <description>GROUP 1 (telematic group):
These patients will have a tablet connected via internet (Telefónica-e-Health). They have to measure their lung function, temperature, pulse oxymetry and symtoms questionnaire every week. The device (tablet) asks them about possible COPD exacerbation. If the patient has an exacerbation, the device offers them a treatment for this exacerbation and it begins a following of this exacerbation until resolution, every day.
The pneumologists will receive an alert in other tablet when the patients have an exacerbation or worsening of their diseases.
The period of monitoring is 1 year.</description>
    <arm_group_label>Group intervention</arm_group_label>
    <other_name>Telematic intervention</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>health care system</intervention_name>
    <description>GROUP 2 (conventional group or control group) Patients with a COPD exacerbation can go to their family physicians or emergency services and these physicians will establish a treatment and a monitoring of these exacerbation (conventional group).
The period of monitoring is 1 year.</description>
    <arm_group_label>Group control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. COPD, which after evaluation of its clinical history, belonging to exacerbator
             phenotype (chronic bronchitic / emphysema) or mixed phenotype (&quot;COPD-asthma&quot;)
             readmission (2 or more income in the previous year) and are stable least six weeks
             before inclusion in the study.

          2. Age over 18 years

          3. The patient or caregiver should be able to use the tablet type telematic tool for
             tracking and monitoring.

        Exclusion Criteria:

          1. Patients with severe comorbidity grade IV heart failure, renal failure on hemodialysis
             or active neoplasia

          2. Patients with difficulties phone coverage

          3. Patients with lack of adequate social and family support.

          4. Patients who do not grant informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaime Corral, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital San Pedro de Alcántara. Cáceres. Spain</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jaime Corral, MD</last_name>
    <phone>+34 927256200</phone>
    <phone_ext>56204</phone_ext>
    <email>jcorral@separ.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juan A Riesco, MD</last_name>
    <phone>+34 927256200</phone>
    <phone_ext>56289</phone_ext>
    <email>jantonio.riesco@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jaime Corral Peñafiel</name>
      <address>
        <city>Cáceres</city>
        <zip>10005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan A Riesco, MD</last_name>
      <phone>+34927256200</phone>
      <phone_ext>56289</phone_ext>
      <email>jantonio.riesco@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Maria A Quiroga, MD</last_name>
      <phone>+34927256200</phone>
      <phone_ext>56289</phone_ext>
      <email>mariansangui@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Cosio BG, Agustí A. Update in chronic obstructive pulmonary disease 2009. Am J Respir Crit Care Med. 2010 Apr 1;181(7):655-60. doi: 10.1164/rccm.201001-0111UP. Review.</citation>
    <PMID>20335383</PMID>
  </reference>
  <reference>
    <citation>Escarrabill J. Discharge planning and home care for end-stage COPD patients. Eur Respir J. 2009 Aug;34(2):507-12. doi: 10.1183/09031936.00146308. Review.</citation>
    <PMID>19648525</PMID>
  </reference>
  <reference>
    <citation>Hurst JR, Fitzgerald-Khan F, Quint JK, Goldring JJ, Mikelsons C, Dilworth JP, Wedzicha JA. Use and utility of a 24-hour Telephone Support Service for 'high risk' patients with COPD. Prim Care Respir J. 2010 Sep;19(3):260-5. doi: 10.4104/pcrj.2010.00035.</citation>
    <PMID>20571731</PMID>
  </reference>
  <reference>
    <citation>Bourbeau J, Julien M, Maltais F, Rouleau M, Beaupré A, Bégin R, Renzi P, Nault D, Borycki E, Schwartzman K, Singh R, Collet JP; Chronic Obstructive Pulmonary Disease axis of the Respiratory Network Fonds de la Recherche en Santé du Québec. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch Intern Med. 2003 Mar 10;163(5):585-91.</citation>
    <PMID>12622605</PMID>
  </reference>
  <reference>
    <citation>Jurado Gámez B, Feu Collado N, Jurado García JC, García Gíl F, Muñoz Gomariz E, Jiménez Murillo L, Muñoz Cabrera L. Home intervention and predictor variables for rehospitalization in chronic obstructive pulmonary disease exacerbations. Arch Bronconeumol. 2013 Jan;49(1):10-4. doi: 10.1016/j.arbres.2012.08.003. Epub 2012 Oct 22. English, Spanish.</citation>
    <PMID>23089685</PMID>
  </reference>
  <reference>
    <citation>De Vries B, Darling-Fisher C, Thomas AC, Belanger-Shugart EB. Implementation and outcomes of group medical appointments in an outpatient specialty care clinic. J Am Acad Nurse Pract. 2008 Mar;20(3):163-9. doi: 10.1111/j.1745-7599.2007.00300.x.</citation>
    <PMID>18336693</PMID>
  </reference>
  <reference>
    <citation>Bischoff EW, Hamd DH, Sedeno M, Benedetti A, Schermer TR, Bernard S, Maltais F, Bourbeau J. Effects of written action plan adherence on COPD exacerbation recovery. Thorax. 2011 Jan;66(1):26-31. doi: 10.1136/thx.2009.127621. Epub 2010 Oct 30.</citation>
    <PMID>21037270</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2018</study_first_submitted>
  <study_first_submitted_qc>April 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2018</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sociedad Española de Neumología y Cirugía Torácica</investigator_affiliation>
    <investigator_full_name>Jaime Corral Penafiel</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>hospitalization</keyword>
  <keyword>telemedicine platform</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

